The Efficacy of Tenofivir to Prevent Perinatal Transmission in Chronic Hepatitis BMothers. AClinical Perspective
Ghassan Mubarak, Richard Ferstenberg – 2 August 2018
Diabetes, Liver Cancer, and Cirrhosis: What Next?
Hannele Yki‐Järvinen, Panu K. Luukkonen – 2 August 2018
Mailed Outreach Invitations Significantly Improve HCC Surveillance Rates in Patients With Cirrhosis: A Randomized Clinical Trial
Amit G. Singal, Jasmin A. Tiro, Caitlin C. Murphy, Jorge A. Marrero, Katharine McCallister, Hannah Fullington, Caroline Mejias, Akbar K. Waljee, Wendy Pechero Bishop, Noel O. Santini, Ethan A. Halm – 2 August 2018 – Hepatocellular carcinoma (HCC) surveillance is associated with early tumor detection and improved survival in patients with cirrhosis; however, effectiveness is limited by underuse. We compared the effectiveness of mailed outreach and patient navigation strategies to increase HCC surveillance in a racially diverse cohort of patients with cirrhosis.
A Novel Mechanism of Starvation‐Stimulated Hepatic Autophagy: Calcium‐Induced O‐GlcNAc‐Dependent Signaling
Yang Shen, Mark J. Czaja – 2 August 2018
Patient‐Reported Outcomes and the Economic Effects of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: The Value Proposition
Zobair M. Younossi – 2 August 2018 – Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) can progress to cirrhosis, hepatocellular carcinoma (HCC), death, or liver transplantation. NASH has also been associated with impaired health‐related quality of life and poses a significant economic burden.
Too Stiff, Too Late . . . Timing Is Everything in Antiangiogenic Treatment of Liver Fibrosis
Thomas Greuter, Vijay H. Shah – 2 August 2018
Ductular Reaction in Liver Diseases: Pathological Mechanisms and Translational Significances
Keisaku Sato, Marco Marzioni, Fanyin Meng, Heather Francis, Shannon Glaser, Gianfranco Alpini – 2 August 2018 – Ductular reaction (DR) is characterized by the proliferation of reactive bile ducts induced by liver injuries. DR is pathologically recognized as bile duct hyperplasia and is commonly observed in biliary disorders. It can also be identified in various liver disorders including nonalcoholic fatty liver disease. DR is associated with liver fibrosis and damage, and the extent of DR parallels to patient mortality.
Safety and Efficacy of Ledipasvir–Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6‐11
Karen F. Murray, William F. Balistreri, Sanjay Bansal, Suzanne Whitworth, Helen M. Evans, Regino P. Gonzalez‐Peralta, Jessica Wen, Benedetta Massetto, Kathryn Kersey, Jiang Shao, Kimberly L. Garrison, Bandita Parhy, Diana M. Brainard, Ronen Arnon, Lynette A. Gillis, Maureen M. Jonas, Chuan‐Hao Lin, Michael R. Narkewicz, Kathleen Schwarz, Philip Rosenthal – 2 August 2018 – Currently, there are no interferon‐free treatments available for hepatitis C virus (HCV)–infected patients younger than 12 years.
A Case of Immune‐Mediated Liver Injury Induced by Olaparib
Manuel Tufoni, Carmen Serena Ricci, Giacomo Zaccherini – 2 August 2018
Lect2 Controls Inflammatory Monocytes to Constrain the Growth and Progression of Hepatocellular Carcinoma
Antoine L’Hermitte, Sandrine Pham, Mathilde Cadoux, Gabrielle Couchy, Stefano Caruso, Marie Anson, Anne‐Marie Crain‐Denoyelle, Séverine Celton‐Morizur, Satoshi Yamagoe, Jessica Zucman‐Rossi, Chantal Desdouets, Jean‐Pierre Couty – 2 August 2018 – Leukocyte cell‐derived chemotaxin‐2 (LECT2) was originally identified as a hepatocyte‐secreted chemokine‐like factor and a positive target of β‐catenin signaling. Here, we dissected out the mechanisms by which LECT2 modulates hepatocellular carcinoma (HCC) development using both HCC mouse models and human HCC samples.